Skip to main content
NCBI home page
The Journal of Hygiene logoLink to The Journal of Hygiene
. 1986 Jun;96(3):491–499. doi: 10.1017/s0022172400066298

Comparison of the immunogenicity, efficacy and safety of 10 micrograms and 20 micrograms of a hepatitis B vaccine: a prospective randomized trial.

E K Yeoh, C L Lai, W K Chang, H Y Lo
PMCID: PMC2129698  PMID: 2942599

Abstract

Four thousand and one hospital staff were screened for hepatitis B virus (HBV) markers in a vaccination programme in Hong Kong. The seropositivity rate for HBsAg, anti-HBs and anti-HBc were significantly higher in the 3160 existing hospital staff than in 841 new recruits. Of the subjects negative for HBV markers, 605 were randomized to receive three doses of either 10 or 20 micrograms of the Merck Institute vaccine (HB-VAX). Compared with the 20 micrograms dose, vaccination with the 10 micrograms dose results in equal immunogenicity and efficacy at the completion of the three injections but induced a slower response rate and lower anti-HBs titres with the first two doses. The commonest side-effect of local soreness was less with the 10 micrograms dose. We conclude that (1) hospital staff working in high endemic areas should be vaccinated on recruitment and (2) the 10 micrograms dose of HB-VAX can replace the recommended 20 micrograms dose for adults, being cheaper and as efficacious.

Full text

PDF
491

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ayoola E. A. The immune response of healthy Nigerian adults to small doses of hepatitis B vaccine: comparison of 10- and 20-micrograms doses. J Med Virol. 1984;13(3):223–225. doi: 10.1002/jmv.1890130304. [DOI] [PubMed] [Google Scholar]
  2. Deinhardt F., Zachoval R., Jilg W., Lorbeer B., Roggendorf M. Immune responses to active and passive-active vaccination against hepatitis B. J Infect. 1983 Jul;7 (Suppl 1):21–25. doi: 10.1016/s0163-4453(83)96534-9. [DOI] [PubMed] [Google Scholar]
  3. Hilleman M. R., Buynak E. B., Roehm R. R., Tytell A. A., Bertland A. U., Lampson G. P. Purified and inactivated human hepatitis B vaccine: progress report. Am J Med Sci. 1975 Sep-Oct;270(2):401–404. doi: 10.1097/00000441-197509000-00025. [DOI] [PubMed] [Google Scholar]
  4. Krugman S., Holley H. P., Jr, Davidson M., Simberkoff M. S., Matsaniotis N. Immunogenic effect of inactivated hepatitis B vaccine: comparison of 20 microgram and 40 microgram doses. J Med Virol. 1981;8(2):119–121. doi: 10.1002/jmv.1890080205. [DOI] [PubMed] [Google Scholar]
  5. McAleer W. J., Buynak E. B., Maigetter R. Z., Wampler D. E., Miller W. J., Hilleman M. R. Human hepatitis B vaccine from recombinant yeast. Nature. 1984 Jan 12;307(5947):178–180. doi: 10.1038/307178a0. [DOI] [PubMed] [Google Scholar]
  6. Mosley J. W., Edwards V. M., Casey G., Redeker A. G., White E. Hepatitis B virus infection in dentists. N Engl J Med. 1975 Oct 9;293(15):729–734. doi: 10.1056/NEJM197510092931501. [DOI] [PubMed] [Google Scholar]
  7. Papaevangelou G. J., Vissoulis C. G., Roumeliotou-Karayannis A. J., Kolaitis N., Krugman S. Comparison of safety and immunogenicity of ADW and AYW hepatitis B vaccines. J Med Virol. 1982;9(3):231–236. doi: 10.1002/jmv.1890090310. [DOI] [PubMed] [Google Scholar]
  8. Papaevangelou G., Roumeliotou-Karayannis A., Vissoulis C., Stathopoulou P., Kolaitis N., Krugman S. Reduction of the dose of hepatitis B vaccine. J Infect. 1983 Jul;7 (Suppl 1):69–70. doi: 10.1016/s0163-4453(83)96718-x. [DOI] [PubMed] [Google Scholar]
  9. Scolnick E. M., McLean A. A., West D. J., McAleer W. J., Miller W. J., Buynak E. B. Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA. JAMA. 1984 Jun 1;251(21):2812–2815. [PubMed] [Google Scholar]
  10. Szmuness W., Stevens C. E., Harley E. J., Zang E. A., Oleszko W. R., William D. C., Sadovsky R., Morrison J. M., Kellner A. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980 Oct 9;303(15):833–841. doi: 10.1056/NEJM198010093031501. [DOI] [PubMed] [Google Scholar]
  11. Szmuness W., Stevens C. E., Zang E. A., Harley E. J., Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981 Sep-Oct;1(5):377–385. doi: 10.1002/hep.1840010502. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Hygiene are provided here courtesy of Cambridge University Press

RESOURCES